ATEC at a glance
Alphatec Holdings, Inc. (ATEC, SEC CIK 1350653) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alphatec Holdings, Inc. (ATEC) reported revenue of $764.2 million (up 25.0% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$0.96.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Alphatec Holdings, Inc. (ATEC) shares worth $393.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Koning John Todd on November 16, 2026 of 14,602 shares at $6.79 per share.
- In the last 90 days, ATEC insiders reported 4 open-market purchases ($1.8M) and 0 open-market sales ($0) on Form 4, a net purchase of $1.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $764.2M
- +25.0% vs prior year
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$1.8M
- 13F holders
- 29 funds
- $393.3M · −2 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Design, manufacture, and sale of spinal surgery medical devices, with polyaxial pedicle screw systems accounting for ~38% of net sales in 2025
- No new products or segments introduced; emphasis on risks related to existing polyaxial pedicle screw systems and licensing compliance
- Strategic focus on managing global regulatory compliance, supply chain risks including tariffs, and AI technology use to mitigate operational and legal risks
- Liquidity: $160.8 million cash and equivalents at year-end 2025; reliance on subsidiaries’ dividends for holding company cash needs emphasized
- Noteworthy risk disclosures on potential natural disasters impacting nearly all operations in wildfire and earthquake zones, and heightened legal/regulatory scrutiny including healthcare laws and intellectual property litigation
Risk Factors
- Litigation settlement and ongoing matters increased litigation-related expenses 143% to $23.8M in 2025
- Exposure to foreign currency exchange risk as international business outside U.S. grows
- Inventory purchase commitment with third-party supplier of $5.0M remaining through December 2025
- Market share challenged by surgeons’ adoption and expansion of competing spine surgery technologies
- $405M principal 0.75% senior convertible notes due 2030 with complex conversion features and capped call hedges
Management Discussion & Analysis
- Forward-looking risks include operating losses, future revenue, expenses, liquidity, and need for additional funding
- Key regulatory challenges: compliance with FDA and international quality requirements
- Business risks: market acceptance, product commercialization, sales network maintenance, and talent retention
- Economic and geopolitical factors, plus public health crises, may materially affect future results
AI summary of the ATEC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $221.2M, up 13% YoY from $196.5M, driven by higher product volume and technology adoption
- Gross margin 71.5% vs 69.9% YoY, based on revenue and cost of sales
- Best performance: product volume growth from expanded surgeon user base and new product portfolio
- Cash $79.9M vs $160.8M at December 31, 2025, with nine-month operating cash flow $40.7M
- Investing cash use $64.4M and financing cash use $57.0M, including surgical instruments, acquisitions, note receivable, and debt repayment
Risk Factors
- No material changes to 10-K risk factors filed February 24, 2026
- Regulatory risk: continued reliance on Section 4(a)(2) exemption for unregistered stock issuances
- Dilution risk: 295,224 unregistered shares issued during the quarter
- Insider-trading compliance risk: executive vice president adopted a Rule 10b5-1 plan covering 159,879 shares
- Compensation risk: equity awards comprise part of director and officer compensation
AI summary of the ATEC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $221M, up 13% year-over-year, with surgical revenue $202M, up 14%
- Hardware revenue grew 17%, case volumes 20%, and net new surgeon users 25%, signaling strong procedural demand
Item 2.02: Results of Operations and Financial Condition
- Press release announces Alphatec’s quarterly financial results for the period ended September 30, 2026
- Exhibit 99.1 contains the detailed results investors need to assess operating performance and financial condition
Item EX-99.1: Item EX-99.1
- Q2 revenue $214M, up 15% year-over-year, with surgical revenue $196M, up 17% on 20% case-volume growth
- Adjusted EBITDA $36M, margin 16.8%, expanding 420 basis points year-over-year
Item 2.02: Results of Operations and Financial Condition
- Press release announces Alphatec’s financial results for the period ended June 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary for investor review
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved the 2026 Equity Incentive Plan, enabling continued equity-based compensation and potential dilution
- Shareholders approved the 2026 Employee Stock Purchase Plan, supporting employee share ownership and retention
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven director nominees elected to one-year terms ending at the 2027 Annual Meeting
- 2026 Equity Incentive Plan approved, authorizing expanded stock-based compensation capacity
AI summaries of ATEC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ATEC
Don't miss the next ATEC filing
- Alerts as it files. A push when ATEC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ATEC, by share count.
- Ask anything. An AI agent that reads every ATEC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Koning John Todd | Buy | Nov 16, 2026 | 14,601.77 | $6.79 |
| Valentine Keith | Buy | Nov 10, 2026 | 35,000 | $6.93 |
| Demski David M | Buy | Oct 30, 2026 | 60,000 | $6.81 |
| Carls Thomas Andrew | A | Oct 5, 2026 | 200,000 | - |
| Miles Patrick | Buy | Sep 10, 2026 | 115,000 | $8.81 |
| Marshall Tyson Eliot | Sell | Aug 5, 2026 | 8,168 | $9.65 |
| MCGINNIS KAREN K | Sell | Jun 11, 2026 | 6,050 | $8.01 |
| MCGINNIS KAREN K | A | Jun 10, 2026 | 32,012 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $611.6M | $764.2M |
| Gross Profit | - | $424.3M | $531.9M |
| Operating Income | - | -$136.2M | -$82.1M |
| Net Income | - | -$162.1M | -$143.4M |
| Gross Margin | - | 69.4% | 69.6% |
| Op. Margin | - | -22.3% | -10.7% |
| Net Margin | - | -26.5% | -18.8% |
| Balance Sheet | |||
| Total Assets | $805.2M | $775.7M | $791.2M |
| Equity | $78.1M | -$14.2M | $12.4M |
| ROE | - | 1144.2% | -1153.7% |
| Per Share | |||
| EPS | - | $-1.13 | $-0.96 |
| Cash Flow | |||
| Operating CF | - | -$44.7M | $45.2M |
| CapEx | - | $83.2M | $42.5M |
Source: XBRL data in Alphatec Holdings, Inc. (ATEC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ATEC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $393.3M |
| Q2 2026 | 31 | $345.7M |
| Q1 2026 | 32 | $412.2M |
| Q4 2025 | 31 | $846.8M |
| Q3 2025 | 30 | $540.7M |
| Q2 2025 | 26 | $354.5M |
| Q1 2025 | 24 | $203.8M |
| Q4 2024 | 20 | $130.7M |
- Millennium Management+996.7K (+87%)
- Morgan Stanley+958.9K (+62%)
- AQR Capital Management+318.7K (+13%)
- Vanguard Portfolio Management LLC+157.3K (+13%)
- Northern Trust+154.2K (+11%)
- Citadel Advisors LLC−2.06M (-84%)
- Two Sigma Investments−539.2K (-65%)
- BlackRock−334.7K (-3%)
- Raymond James Financial−161.1K (-10%)
- Bank of America Corp−79.3K (-4%)
- Marex Group plc+32.0K
- PARK NATIONAL CORP /OH/+12.3K
- FMR LLC (Fidelity)−925.7K
- Renaissance Technologies LLC−284.5K
- Franklin Resources−64.6K
- M&T Bank−12.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ATEC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ATEC SEC filings: frequently asked questions
Are ATEC insiders buying or selling?
In the last 90 days, Alphatec Holdings, Inc. (ATEC) officers, directors and 10% owners reported 4 open-market purchases worth $1.8 million by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ATEC stock?
As of September 30, 2026, the largest Alphatec Holdings, Inc. (ATEC) holders among the 13F filers tracked by SignalX were BlackRock ($113.4 million), Vanguard Capital Management LLC ($53.8 million), State Street Corp ($36.9 million), AQR Capital Management ($27.9 million), Morgan Stanley ($25.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ATEC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alphatec Holdings, Inc. (ATEC) reported revenue of $764.2 million (up 25.0% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$0.96. The figures come from the XBRL data in the 10-K.
What are the main risks in ATEC's latest 10-K?
In the 10-K filed February 24, 2026, Alphatec Holdings, Inc. (ATEC) flagged: Litigation settlement and ongoing matters increased litigation-related expenses 143% to $23.8M in 2025. Exposure to foreign currency exchange risk as international business outside U.S. grows. (AI summary of the Risk Factors section.)
What did ATEC report in its latest 8-K?
Alphatec Holdings, Inc. (ATEC) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $221M, up 13% year-over-year, with surgical revenue $202M, up 14%.
What are the latest ATEC SEC filings?
Alphatec Holdings, Inc. (ATEC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.
What is ATEC's SEC CIK number?
Alphatec Holdings, Inc. (ATEC)'s SEC Central Index Key (CIK) is 1350653. EDGAR lists every ATEC filing under that number.
Ask anything about ATEC
The research agent reads ATEC's filings, financials, insider trades and 13F holders, then answers with sources.